Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949668 | 0.84 | MLYCD (0.41) | KMT2AMEN1TDP1MLYCDLMNA | |
| SCHEMBL343793 | 0.82 | KMT2A (0.50) | KMT2AMEN1MLYCDRAB9AMAPT | |
| SCHEMBL31058225 | 0.82 | RORC (0.42) | KMT2AMEN1TDP1LMNARAB9A | |
| SCHEMBL3500057 | 0.81 | MEN1 (0.49) | KMT2AMEN1TDP1MLYCDLMNA | |
| SCHEMBL31058184 | 0.78 | MLYCD (0.36) | KMT2AMEN1MLYCDLMNARAB9A | |
| SCHEMBL19553778 | 0.76 | LMNA (0.36) | MLYCDLMNARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19553964 | 0.76 | ALDH1A1 (0.43) | KMT2AMEN1TDP1MLYCDLMNA | |
| SCHEMBL3676123 | 0.75 | NPC1 (0.47) | KMT2AMEN1MLYCDLMNARAB9A | |
| SCHEMBL6628 | 0.74 | KMT2A (0.49) | KMT2AMEN1TDP1LMNARAB9A | |
| SCHEMBL9681020 | 0.73 | KMT2A (0.42) | KMT2AMEN1LMNARAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094688-A | Compositions and methods for treating pulmonary arterial hypertension | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | NINGBO MEISHAN BONDED PORT AREA ZHEJIANG UNITED INVESTMENT MANAGEMENT CO., LTD. (CN) | 2025-07-31 | — | — | US | disclosed |
| CN-119997953-A | Alpha protein kinase 1 inhibitors for the treatment of kidney diseases and kidney related diseases | 上海药苑生物科技有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4543443-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025082485-A1 | COMPOSITION AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2025-04-24 | — | — | WO | disclosed |
| CN-112110811-B | Preparation method of bilastine intermediate | 北京万全德众医药生物技术有限公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | XU, Cong (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240109853-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | TIANJIN HONGKE BAISHI QIXIN VENTURE CAPITAL PARTNERSHIP (LIMITED PARTNERSHIP) (CN) | 2024-04-04 | — | — | US | disclosed |
| WO-2024002270-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2024-01-04 | — | — | WO | disclosed |
| CN-116670133-A | Alpha protein kinase 1 inhibitors and methods of use | 上海药苑生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4222151-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | Shanghai Yao Yuan Biotechnology Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023143603-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2023-08-03 | — | — | WO | disclosed |
| WO-2022222888-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022063152-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2022-03-31 | — | — | WO | disclosed |
| EP-2393811-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | Pfizer Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089686-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-D]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | PFIZER INC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197591-A1 | 4-AMINO-7,8-DIHYDROPYRIDO[4,3-d]PYRIMIDIN-5(6H)-ONE DERIVATIVES | CDK7, DPYD, DHFR | KMT2A 3053/4885MEN1 678/4885TDP1 1885/4885 |
| US-20240226094-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KAWASAKI DISEASE | PHKA1, PHKA2, PHKG1 | KMT2A 3181/4885MEN1 3234/4885TDP1 819/4885 |
| US-20240109853-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS AND METHODS OF USE | PHKA1, PHKA2, PHKG1 | KMT2A 2978/4885MEN1 2806/4885TDP1 654/4885 |
| US-20250241908-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING ATHEROSCLEROSIS AND RELATED DISEASES | PHKA1, PHKA2, PHKG1 | KMT2A 2582/4885MEN1 3169/4885TDP1 591/4885 |
| US-20250381196-A1 | ALPHA PROTEIN KINASE 1 INHIBITORS FOR USE IN TREATING KIDNEY DISEASES AND KIDNEY-RELATED DISEASES | PHKA1, PHKA2, PHKG1 | KMT2A 2191/4885MEN1 3121/4885TDP1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.